AIM Specialty Health AIM Specialty Health

Press Releases

FOR IMMEDIATE RELEASE

AIM Specialty Health Appoints Oncology Medical Director for Value-Based Solutions to Cancer Care

Dr. Michael Fisch brings nationally recognized clinical practice, research, academic and community oncology experience

CHICAGO -- April 14, 2015 – AIM Specialty Health has appointed Michael Fisch, MD, MPH, FACP, FAAHPM, formerly  of  MD Anderson Cancer Center, as medical director for Medical Oncology. He will work closely with the executive leadership team and provide clinical expertise for the continued expansion of the AIM Oncology Solution, which today serves more than 13 million health plan members across the country.

Dr. Fisch served as the founding chair of the Department of General Oncology for MD Anderson Cancer Center, one of the nation's most highly respected providers of oncology care. In his role as professor and chair at the center, Dr. Fisch led a group of clinical faculty who manage a broad mix of cancer patients in a variety of community and academic settings and those involved in research.

“Dr. Fisch brings outstanding experience to AIM and our clients," said Brandon Cady, AIM president and CEO. "From a vantage point in community oncology and as a researcher and leader within influential scientific and patient advocacy organizations, he brings a unique perspective to patient care and deep knowledge of the challenges associated with cancer care today.”

“As a practicing oncologist, I am acutely aware of the impact that unnecessary variation in cancer care delivery has on patients and families and how this  impacts the quality, safety, and cost of care,” said Fisch.  “I chose to join this authentic, multidisciplinary team because I see the AIM approach as an effective way to influence oncology care towards higher quality and value for millions of people. The AIM Oncology Solution is grounded in evidence-based medicine and rooted in the Institute of Medicine’s six aims for improvement of healthcare.”

Dr. Fisch joins a clinical team that already includes Stacey Ban, MD, associate medical director for Medical Oncology, and Robert Zimmerman, MD, associate medical director for Radiation Oncology.  Board certified in medical oncology and hematology, Dr. Ban has been instrumental in the launch and ongoing operational management of the AIM Oncology Solution, including the development of cancer treatment pathways. Dr. Zimmerman is board certified in radiation oncology, and provides clinical leadership over AIM programs driving the most effective use of radiation therapy as part of cancer care. 

"Having the right clinical expertise is critical in helping address the challenges that our clients face as they manage escalating costs for cancer care while also helping ensure members receive the most clinically appropriate care available," said Cady. "The depth of clinical knowledge and experience within our oncology team shows AIM’s commitment to leading the oncology management market space and provides superb clinical leadership resources for our clients to leverage within their provider partnerships and customer relationships.”



Contact: AIM Specialty Health

Lori McLaughlin 317.407.7403

Lori.McLaughlin2@wellpoint.com

#          #          #

About AIM
AIM Specialty Health® is focused on driving appropriate, safe and affordable care through the healthcare system. For more than 40 million members covered across 50 states, D.C. and US territories, AIM targets the quality and cost of clinical services including radiology, cardiology, oncology, specialty drugs and sleep medicine. As a national leader in specialty benefits management, AIM helps health plans, providers and employers focus on the value of health decisions with an integrated suite of solutions combining clinical excellence, technology and superior customer service. AIM is a wholly owned subsidiary of Anthem, Inc. www.aimspecialtyhealth.com.

 

            #